In the setting of total neoadjuvant therapy (TNT) for locally advanced rectal cancer, would you consider using FOLFIRI instead of FOLFOX/CAPOX for consolidative chemotherapy in patients unable to receive oxaliplatin, with the goal of maximizing the chance of clinical complete response and facilitating non-operative management?